News

Vaccine vs placental malaria
Enlarge image

FundingEUGermanyFranceDenmark

Vaccine vs placental malaria

04.03.2013 - Researchers from the PlacMalVac project have bagged €6m from the EU to start clinical trials of a placental malaria vaccine.

Pregnant women are particularly vulnerable to malaria, due to a particular type of pathology. Their infected blood cells clump together in the placenta, leading to growth retardation and preterm delivery, which in turn cause higher infant mortality. For the first time, a EU consortium of 5 partners led by University of Copenhagen will now begin clinical trials with a vaccine that blocks that blood aggregation in placenta-associated malaria (PAM). It targets the var2CSA protein, which causes aggregation of Plasmodium falciparum-infected erythrocytes by adhesion to the primary placental adherence receptor, chondroitin sulphate A (CSA), present in the placental intervillous blood spaces. Infected mice not carrying var2CSA do not show the PAM-associated effects.

“This will be the first clinical trial using the parasite antigens", said project coordinator Thor G. Theander from the University of Copenhagen. "The vaccine attempts not to eliminate the infection but to eliminate the disease. At Centre for Medical Parasitology we are all thrilled to have this opportunity. It marks an intermediate highpoint of many years of committed research.”

In previous projects supported by the Danish National Advanced Technology Foundation, Theander's team defined a smaller region of multi-domain protein var2CSA. Overall they identified three antigenic regions within it that are crucial for blocking PAM in rats. "We managed proof of concept for the malaria vaccine and we are currently addressing manufacturability of the vaccine. The funding from EU FP7 will enable us to continue the development including upstream and downstream process development, GMP production, Phase Ia and Ib human clinical trials, as well as preparations for Phase II clinical trials."

Theander now heads the EU consortium, which includes University of Copenhagen, ExpreS2ion Biotechnologies (Denmark), Institut de Recherche pour le Développement (France), Université d'Abomey-Calavi (Benin), University of Tübingen and the European Vaccine Initiative (EVI). The EVI has mobilised further €10m for the development of PAM vaccines within the projects PRIMALVAC and PAMCPH.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/vaccine-vs-placental-malaria.html

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

RegulationUKFranceGermanySpain

01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.

RegulationItalyGermanyNetherlandsEU

28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.

Events

All Events

Current issue

All issues

Product of the week

Products